Block view of the study programme

		Or	Th	Pr	Au	Cr
Block 1						
Compulsory courses						
PHIN2034-1	*Biotechnologies*	TA				**7**
	- Concepts and production of protein and oligonucleotide biopharmaceuticals - David VERMIJLEN		15	-	-	
	- Living biopharmaceuticals, vaccines and biosecurity - Véronique FONTAINE		6	-	-	
	- Managing the risk of the release of cell and genetic products - Roland MARINI DJANG'EING'A		3	-	-	
	- Formulation of biopharmaceuticals - Rita VANBEVER		15	-	-	
	- Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part A - Marianne FILLET		5	-	-	
	- Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part B (post-translational modifications) - Cédric DELPORTE		3	-	-	
	- From the laboratory to the pharmacy: legal requirements - part a: Patents and industrial protection - Patrick DI STEFANO		5	-	-	
	- From the laboratory to the pharmacy: legal requirements - part b: Statutes and regulatory constraints on biological products - Hugues MALONNE		3	-	-	
	- From the laboratory to the pharmacy: legal requirements - part c: Procedure for releasing batches and the legal framework of vaccines - Lorenzo TESOLIN		1	-	-	
	- From the laboratory to the pharmacy: legal requirements - part d: Organisation of quality assurance - Thierry PRONCE		3	-	-	
	- From the laboratory to the pharmacy: legal requirements - part e: Introduction to Biobanking - Stéphanie GOFFLOT		3	-	-	
PHIN2004-1	*Active substances*	TA				**4**
	- Substances issues de recherches pharmacochimiques, part a		10	-	-	
	- Substances issues de recherches pharmacochimiques, part b - François DUFRASNE		5	-	-	
	- Substances d'origine naturelle, part a - Joëlle LECLERCQ		5	-	-	
	- Substances d'origine naturelle, part b - Caroline STEVIGNY		5	-	-	
	- Produits radiopharmaceutiques - Zena WIMANA		10	-	-	
PHIN2008-2	*Clinical viewpoints*	TA				**5**
	- Métabolisme des médicaments et paramètres pharmacocinétiques - FrançoisXavier MATHY		20	-	-	
	- Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis RADERMECKER		15	-	-	
	- Information et pharmacovigilance - Raphaël DENOOZ		10	-	-	
PHIN2013-2	*Quality assurance and pharmaceutical management*	TA				**7**
	- Principles of pharmaceutical management - JeanMichel VANDERHOFSTADT		10	-	-	
	- Quality assurance, part a: basic concepts and quality assurance organisation - Thierry PRONCE		18	-	-	
	- Quality assurance, part b: analytical technology of procedures and risk analysis - Xavier MARCELIS		10	-	-	
	- English applied to the pharmaceutical industry - Jacques POUPAERT, Nevin SERBEST		20	-	-	
	- Pharmaceutical marketing - Vincent BIERLAIRE		7,5	-	-	
PHIN2033-1	*Pharmaceutical technology*	TA				**5**
	- Industrial pharmaceutical microbiology - Véronique FONTAINE		9	-	-	
	- Preformulation and selection of galenical forms - Jonathan GOOLE		15	-	-	
	- Industrial production of galenical forms - Brigitte EVRARD		15	-	-	
	- Industrial aspects of technological development including packaging - Laurence DENIS		10	-	-	
PHIN2023-1	*Drug analysis*	TA				**6**
	- Analytical control practices and pharmaceutical and biopharmaceutical		7	-	-	

	control - part a - Pierre VAN ANTWERPEN - *Analytical control practices and pharmaceutical and biopharmaceutical control - part b* - Marianne FILLET		5	-	-	
	- *Pharmaceutical and biopharmaceutical analytical methods - Approving and certifying equipment* - Philippe HUBERT, Roland MARINI DJANG'EING'A		12	-	-	
	- *Pharmaceutical and biopharmaceutical analytical methods - Process Analytical Technology* - Eric ZIEMONS		5	-	-	
	- *Statistical methods applied to the pharmaceutical industry* - Laure ELENS		15	-	-	
	- *Experimental planning and quality by design* - Bruno BOULANGER, Pierre LEBRUN		10	-	-	
PHIN2029-2	*Regulation and the medical-social environment*	TA				**8**
	- *Economic aspects of drug development* - Dominique MARTIN		10	-	-	
	- *Legislation and procedures applied to pharmaceutical industry - part a: Leglislation* - Catherine DRUEZ		10	5	-	
	- *Legislation and procedures applied to pharmaceutical industry - part b: Patents and industrial protection* - Patrick DI STEFANO		5	-	-	
	- *Macroeconomic environment and pharmaco-economics* - Hugues MALONNE		10	-	-	
	- *CTD File (Common Technical Document)* - Walid EL AZAB		15	-	-	
	- *Regulations of preclinical and clinical studies: Pharmaceutical toxicological files* - Karen VAN MALDEREN		15	-	-	
	- *Regulations of preclinical and clinical studies: Clinical studies* - Anne LENAERS		5	-	-	
	- *Regulations of preclinical and clinical studies: Pediatric studies* - Thierry SCHURMANS		2,5	-	-	
	- *Specific regulatory issues, part a: medicine and herbal dietary supplement* - Michel FREDERICH		5	-	-	
	- *Specific regulatory aspects, part b: Preformulation and documentation of galenic development* - Francis VANDERBIST		5	-	-	
	- *Belgian and European legislation on clinical trials*		5	-	-	
PHIN2032-1	*Visits and seminars organised in the pharmaceutical industry* - François DUFRASNE, Marianne FILLET, Joëlle LECLERCQ, Rita VANBEVER - [75h Vis.]	TA	-	-	[+]	**3**
MTFE2000-1	*End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab* - François DUFRASNE, Philippe HUBERT, Joëlle LECLERCQ - [12w STCO]	TA	-	-	[+]	**15**